Tweets
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/4WRpwh8iRa https://t.co/ZGKDqfjb7Y
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/gGsBr1s0RE https://t.co/Ku6tdzit84
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR.
https://t.co/XQL7bfkkho https://t.co/HJ2aSIG0rn
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
Spinal CT study of 40 ankylosing spondylitis pts shows the most common site and region of intervertebral fusion were the posterior vertebrae of the middle thoracic region >50% halffused posterior vertebrae Th4–Th5 to Th7–Th8, followed by Cx, last lumbar https://t.co/HzJmpROJmr https://t.co/9qUwlGyBQz
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/JLGIgALUip https://t.co/boTTzrixk9
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/cgC837Na81 https://t.co/bndKVqNsSE
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/F0aQR7ZDeU https://t.co/ugXkDmOVML
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/uJjr7rTIJe https://t.co/ptTvwWJlvO
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 10 months ago
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/YQW2wN9X25 https://t.co/BS9jZRLUo4
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 11 months ago
Composite Measures to Inform Treatment Choices in Bio-naïve Patients with PsA
What is an option for treating and managing bio-naïve patients with PsA?
Dr. Mease and Dr. Khattri discuss.
Therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/xha5gyHqor https://t.co/mINKK0ybVD
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 11 months ago
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/4k6DNJie4n https://t.co/BbPlEFAGH3
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 11 months ago
Paradoxical Rxns (PR) & biologics in TReasure database: 2867 RA & 5316 SpA pts; 5-yr FUV found 136 pts (1.7%) developed the PRs; 60% w/ 1st biologic, after median 12 mos, 93% psoriais (pustular 60%, palmoplantar 31%), many better w/ another TNFi https://t.co/5tybXZZVKW https://t.co/1nQaXQOEDD
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 11 months ago


